RxDoctor Payments Data

Elias Frangos, PA

Medical · Apple Valley, CANPI 1235697376

Payments from drug & device makers

$510in general payments, 2019–2025

Across 9 payments — averaging $56.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$140
  • AstraZeneca$123
  • Boehringer Ingelheim$108
  • Esperion Therapeutics, Inc.$79
  • Johnson & Johnson$38
  • Medtronic$21

What the payments were for

  • Food & beverage$42283%
  • Education$8817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 50th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$255,474
Medicare patients
495
Services billed
2,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$93,839
EntrestoSacubitril/Valsartan46$34,488
XareltoRivaroxaban27$22,413
JardianceEmpagliflozin16$16,375
BrilintaTicagrelor21$15,236
FarxigaDapagliflozin Propanediol21$14,336
Metoprolol Succinate90$737
Ranolazine ErRanolazine19$701
Atorvastatin Calcium52$588
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$546
Potassium Chloride17$496
Metolazone12$474
Digoxin25$401
Metoprolol Tartrate36$375
Ezetimibe11$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$123$29,57242 claims
Johnson & JohnsonXarelto$38$22,41327 claims
Boehringer IngelheimJardiance$108$16,37516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,087 medical providers in California.

Other medical in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →